Steroid and xenobiotic receptor (SXR) is activated by endogenous and exogenous chemicals including steroids, bile acids, and prescription drugs. SXR is highly expressed in the liver and intestine, where it regulates cytochrome P450 3A4 (CYP3A4), which in turn controls xenobiotic and endogenous steroid hormone metabolism. However, it is unclear whether Food and Drug Administration (FDA)-approved plasticizers exert such activity. In the present study, we evaluated the effects of FDAapproved plasticizers on SXR-mediated transcription in vitro by luciferase reporter, SXR-coactivator interaction, quantitative realtime PCR analysis of CYP3A4 expression, CYP3A4 enzyme activity assays, and SXR knockdown. Rats, treated with gavage and intraperitoneal injection of compounds, were examined for CYP3A1 expression in vivo. We found that four of eight FDAapproved plasticizers increased SXR-mediated transcription. In particular, acetyl tributyl citrate (ATBC), an industrial plasticizer widely used in products such as food wrap, vinyl toys, and pharmaceutical excipients, strongly activated human and rat SXR. ATBC increased CYP3A4 messenger RNA (mRNA) levels and enzyme activity in the human intestinal cells but not in human liver cells. Similarly, CYP3A1 mRNA levels were increased in the intestine but not the liver of ATBC-treated rats. These in vitro and in vivo results suggest that ATBC specifically induces CYP3A in the intestine by activating SXR. We suggest that ATBC-containing products be used cautiously because they may alter metabolism of endogenous steroid hormones and prescription drugs.
The orphan nuclear receptor (NR) steroid and xenobiotic receptor (SXR) (also known as pregnane X receptor [PXR] ) is activated by endogenous and exogenous chemicals, including steroids, bile acids, and prescription drugs. SXR is highly expressed in the liver and intestine, where it regulates genes that control xenobiotic and endogenous steroid hormone metabolism. SXR binds to xenobiotic-response elements (XREs) located in promoters of genes that encode phase I cytochrome P450 (CYP) enzymes, phase II conjugating enzymes (e.g., UDP glucuronosyltransferase 1A1), and phase III drug transporters (e.g., P-glycoprotein/multidrug resistance protein 1 [MDR1]) (Kliewer et al., 2002; Zhang et al., 2008; Zhou et al., 2009) .
Induction of these drug-metabolizing genes by SXR can cause drug-drug interactions. For example, the antibiotic rifampicin (RFP) is an SXR agonist that reduces plasma concentrations of oral contraceptives, glucocorticoid derivatives, calcium channel blockers, and cyclosporine. Further, SXR activation may alter the local bioavailability of androgens, estrogens, and 1,25(OH) 2 D 3 (1,25-D 3 ). Long-term treatment with RFP or antiepileptic drugs (e.g., phenobarbital, carbamazepine, and phenytoin) can cause vitamin D deficiency or osteomalacia (Brodie et al., 1980; Kulak et al., 2004) . Several recent studies have reported that CYP3A4 plays the dominant role in the 23-hydroxylation and 24-hydroxylation of 1,25-D 3 in the small intestine and liver (Xu et al., 2006; Zhou et al., 2006) . Similarly, the SXR activator pregnenolone-16a-carbonitrile (PCN) exhibited PCN-dependent loss of mineral density in the metaphyseal bones of mice (Konno et al., 2009) .
We and others have previously shown that endocrine disrupting chemicals, the widely used plasticizer diethylhexyl phthalate (DEHP), and bisphenol A increase SXR-mediated transcription of CYP3A4 and MDR1 in humans (Masuyama et al., 2000; Takeshita et al., 2001 Takeshita et al., , 2006 ; however, it is unclear whether Food and Drug Administration (FDA)-approved plasticizers used for food contact applications and pharmaceutical excipients activate SXR.
Here, we used a reporter assay to evaluate the ability of eight FDA-approved pharmaceutical plasticizers (U.S. Food and Drug Administration [USFDA] , 2010a) to activate SXR. We then focused on acetyl tributyl citrate (ATBC) ; empirical formula, C 20 H 34 O 8 ; MW, 402.5; Fig. 1 ), which showed the strongest effect on SXR-mediated transcription. The response to ATBC in various species was evaluated by a reporter assay, and tissue-specific ATBC effects were assessed in liver and intestinal cells. The in vivo action of ATBC was confirmed in the liver and intestine of rats.
MATERIALS AND METHODS
Materials. RFP, PCN, acetyl triethyl citrate, epoxidized linseed oil, and epoxidized soybean oil were obtained from Sigma-Aldrich (St Louis, MO). ATBC, triethyl citrate, diethyl phthalate, dibutyl phthalate, dibutyl sebacate, and diacetyl monolauryl glyceride were from Wako (Osaka, Japan). Tributyl citrate and triacetin were from Tokyo Chemical Industry (Tokyo, Japan), and 1,25-D 3 was purchased from BIOMOL (Plymouth Meeting, PA). Cardizem CD 300-mg capsules were from Aventis Pharmaceuticals (Kansas City, MO). The polyvinylidene chloride (PVDC)-containing Saran Ò Wrap (corresponding to Saran Original in USA) was supplied by Asahi Kasei (Tokyo, Japan), and the polyethylene-containing GLAD Ò Wrap was supplied by Clorox Company of Canada (Brampton Ontario, Canada). Monoclonal mouse antibodies against steroid receptor coactivator 1 (SRC1), transcriptional intermediary factor 2 (TIF2), and thyroid hormone receptor activator molecule 1 (TRAM1) were described previously (Igarashi-Migitaka et al., 2005) . Cryopreserved human hepatocytes (lot LMP, 38-year-old Caucasian woman) were purchased from In Vitro Technologies (Baltimore, MD). LS174T cells were obtained from American Type Culture Collection. Cryopreserved HepaRG Ò cells were purchased from Biopredic International (Rennes, France). FLC-5 and FLC-7 cells were gifts from Dr Y. Ishizuka (Applied Cell Biotechnologies, Yokohama, Japan).
ATBC extraction from Cardizem CD. The contents of ten 300-mg Cardizem CD capsules (diltiazem hydrochloride) were ground to a white powder (7.2 g). To extract organic compounds, 250 ml ethyl acetate was added. After 3 h stirring at room temperature, the suspension was filtered, and the residual mass was washed with 200 ml ethyl acetate. The filtrate and washings were combined and evaporated to give a viscous oil, which was purified by silica gel column chromatography (hexane:ethyl acetate [15:1], followed by toluene:ethyl acetate [10:1]). To confirm its identity, ATBC obtained by chromatography was compared with commercially available ATBC by spectroscopic analysis ( 1 H-NMR and high resolution mass spectrometry) (Nara et al., 2009) .
Plasmids. Mouse PXR1 in pSG5 (Kliewer et al., 1998) was kindly provided by Dr. DJ Mangelsdorf (Southwestern Medical Center, Dallas, TX). Human SXR in pCDG1 and GAL4 SXR-LBD, containing the ligand-binding domain (LBD) of human SXR (amino acids [aa] 107-434) in the pM expression vector (Clontech), were described previously (Takeshita et al. 2002) . GAL4 mouse SXR-LBD was created by PCR amplification of mouse PXR1 (aa 107-434).
GAL4 fusion constructs containing the LBD of rat, beagle, and rabbit SXR (GAL4 SXR-LBD) in the pCMX vector were kindly provided by Dr B Blumberg (University of California, Irvine, CA) (Milnes et al., 2008) . The plasmid GAL4 SRC-1-RID containing three LXXLL motifs of human SRC1 and VP16 SXR-LBD in the AASV-VP16 vector were described previously (Takeshita et al., 2002) . The plasmid GAL4 TIF2-RID containing human TIF2 (aa 593-770) (Voegel et al., 1996) was constructed by ligating the homologous region of SRC1-RID into the pM expression vector. VP16 SXR-LBD (DAF2), the activation function 2 (AF2) truncation mutant of VP16 SXR-LBD (aa 107-419), was created by PCR amplification using an antisense primer containing a stop codon mutated at F420. The luciferase (LUC) reporter construct, 53 upstream activating sequence (UAS)-TK-LUC, the xenobiotic-responsive enhancer module (XREM)-CYP3A4-LUC, MDR1-TK-LUC, and MUT-MDR1-TK-LUC were described previously (Takeshita et al., 2002 (Takeshita et al., , 2006 . The plasmid phRL-TK was purchased from Promega (Madison, WI).
Transient cotransfection experiments. CV-1 cells were grown without antibiotics in DMEM and 10% fetal calf serum (FCS) stripped of hormones by resin and activated charcoal. Cells were transiently transfected using the calcium phosphate coprecipitation method in 24-well plates with 500 ng reporter plasmid (XREM-CYP3A4-LUC, MDR1-TK-LUC, or 53 UAS-TK-LUC) and 100 ng expression vector; 100 ng phRL-TK was used as internal control. Empty expression vector was transfected into some cells to equalize total plasmid concentration. Cells were treated for 24 h and then analyzed with the DualLuciferase Reporter Assay System (Promega). The firefly luciferase activity of the reporter was corrected by Renilla luciferase activity of the control plasmid and expressed relative to the untreated control. Transfection studies (three wells per treatment) were repeated at least twice. Representative results are expressed as mean ± SD (n ¼ 3).
Immunohistochemistry. Animal protocols were approved by the Institutional Animal Care and Use Committee of St Marianna University, Kawasaki, Japan. For immunohistochemistry experiments, the duodenum from a 5-week-old male Wistar rat and liver from a 7-week-old male SpragueDawley rat were fixed in 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.3). Specimens were embedded in paraffin, and 3-lm sections were stained for SRC1, TIF2, or TRAM1 as described previously (Igarashi-Migitaka et al., 2005) Representative results are expressed as mean ± SD (n ¼ 3 wells per treatment) of two independent experiments. CYP3A4 activity. To determine the effects of test compounds on CYP3A4 activity in LS174T cells, we used the P450-Glo CYP3A4 Assay with Luciferin-IPA (Promega) according to the manufacturer's instructions. Briefly, LS174T cells were grown with Opti-MEM I medium and 10% FCS in collagen-coated 96-well plates with clear bottoms (Collagen 1 BD BioCoat; BD Biosciences, Franklin Lakes, NJ). Cells were treated with test compounds (four wells per treatment) or 0.1% DMSO. Cell culture medium without cells served as the background control. After the 48-h treatment, cells were incubated with 4lM Luciferin-IPA for an additional 60 min. An aliquot of the medium was then combined with an equal volume of the luciferin detection reagent in a white luminometer plate, and luminescence was read. The remaining cells were assessed using the Cell Titer-Glo Luminescent Cell Viability Assay (Promega) to estimate the cell number in each well, and CYP3A4 activity was normalized to cell number. Representative results from two independent experiments are expressed as mean ± SD (n ¼ 4).
In vivo studies. Animal procedures were approved by the Institutional Animal Care and Use Committee of Gunma University, Maebashi, Japan. Sevenweek-old male Wistar rats received PCN (50 mg/kg), ATBC (5 or 50 mg/kg), or DMSO (1 ml/kg) by intraperitoneal injection for three consecutive days (each group, n ¼ 3). Alternatively, each group (n ¼ 3) of rats was treated with 50 mg/ kg/day PCN or ATBC by daily gavage for 2 days. Corn oil was used as a vehicle for all compounds. Twenty-four hours after the last treatment, the rats were euthanized. During the last 24 h, access to food was temporarily denied to all rats and only drinking water was supplied to avoid a possible influence on CYP induction by food. Total RNA was prepared from liver, duodenum, and ileum using TRIzol reagent (Invitrogen), and cDNA was synthesized using PrimeScript RT (Takara Bio, Otsu, Japan). Then, qRT-PCR was performed with rat CYP3A1 primers (see Supplementary Table 1) or rodent GAPDH primers (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems). Results were normalized to GAPDH using the 2 ÀDDCt method and expressed relative to the untreated controls (mean
Statistical analysis. Groups were compared by the Mann-Whitney U-test; p < 0.05 was considered significant in all cases. Statistical analysis was carried out with StatView 5.0 software for Macintosh (SAS Institute, Cary, NC).
RESULTS

Pharmaceutical Excipients Activate SXR
We evaluated eight FDA-approved plasticizers to determine their ability to activate human SXR, including four citrate esters (ATBC, tributyl citrate, acetyl triethyl citrate, and triethyl citrate), two phthalates (diethyl phthalate and dibutyl phthalate), dibutyl sebacate, and triacetin. CV-1 monkey kidney fibroblasts were cotransfected with a human SXR expression vector and the reporter XREM-CYP3A4-LUC, in which the enhancer and promoter of CYP3A4 drive luciferase gene expression (Goodwin et al., 1999) . We found that ATBC, tributyl citrate, acetyl triethyl citrate, and dibutyl phthalate activated SXR ( Fig. 2A) . ATBC was the most potent inducer of transcription; therefore, we focused on ATBC in subsequent studies. ATBC dose dependently activated SXR, producing a greater effect than RFP, known to be a strong activator of SXR (Fig. 2B ). We tested whether ATBC upregulates the SXR target MDR1 using the reporter MDR1-TK-LUC, which contains the DRþ4 motif of MDR1-XRE fused to the heterologous thymidine kinase (TK) promoter (see Supplementary Figure 1A) , and the mutated DRþ4 reporter control, MUT-MDR1-TK-LUC (see Supplementary Figure 1B) . Previous studies reported that SXR cannot dimerize with RXR on the mutated DRþ4 element and was not activated by RFP in a transfection-based reporter assay (Geick et al., 2001; Takeshita et al., 2006) . Similarly, we observed that ATBC and RFP increased transcription from the wild type but not the mutated MDR1-XRE. The activation function of ATBC on nuclear receptor-mediated transcription is SXR specific because ATBC did not stimulate other nuclear receptors, including human estrogen receptor a and b, human PPAR c, human thyroid hormone receptor b, human progesterone receptor 1, and human androgen receptor, or human glucocorticoid receptor-mediated transcription as measured using luciferase reporter assays (see Supplementary Figure 2 ).
ATBC as a Pharmaceutical Excipient
The online FDA database states that five oral drugs contain ATBC (0.56-57.55 mg) (USFDA, 2010b); however, these drugs were not identified. We therefore conducted an internet search and found that Cardizem CD, which is widely used to treat hypertension and angina pectoris, contains ATBC as an inactive ingredient. Using silica gel column chromatography, we obtained 126 mg ATBC from ten 300-mg Cardizem CD capsules. Because the maximum daily dose is 480 mg, patients taking Cardizem CD may be exposed to as much as 20.2 mg ATBC daily.
ATBC Leaching from PVDC Wrap Activates SXR
ATBC is regarded as a relatively nontoxic material and is therefore used in food wrap. We recently reported that~18% of ATBC leach from PVDC cling wrap into skim milk heated to 60°C (Nara et al., 2009 ). Therefore, we tested whether SXR agonistic activity can be detected in an aqueous solution exposed to PVDC wrap. Two 2-cm squares of PVDC (~7 mg) or polyethylene wrap was immersed in 4 ml DMEM containing 10% charcoal-stripped FCS at 37°C for 30 min or 2 h, and the medium was evaluated with the XREM-CYP3A4-LUC reporter. Since the ATBC content of the PVDC wrap is~5% (wt/wt) (Nara et al., 2009), we estimated an ATBC concentration of 20lM if 10% of the ATBC content leached into 4 ml of medium. In this experiment, we observed that medium exposed to PVDC wrap activated SXR in a time-dependent manner, whereas medium exposed to polyethylene wrap did not (Fig.  2C) . The Japan Hygienic Association of Vinylidene Chloride reports that the PVDC wrap used in this study contains ATBC and diacetyl monolauryl glyceride as plasticizers and epoxidized soybean oil and/or epoxidized linseed oil as stabilizers (Japan Hygienic Association of Vinylidene Chloride, 2010). We therefore tested all of the additives individually (see Supplementary Figure 3 ) and observed that only ATBC increased SXR-mediated activation of the CYP3A4 promoter. 
ATBC Activates SXR in Other Species
The SXR LBD amino acid sequence varies greatly across species. Although human and mouse SXR genes share 96% identity in the DNA-binding domain (DBD), they share only 77% amino acid identity in the LBD (Jones et al., 2000) , leading to different xenobiotic responses. Thus, RFP strongly activates SXR in humans but not in rats or mice. Conversely, PCN strongly activates SXR in rats and mice but not in humans (Jones et al., 2000; LeCluyse, 2001) . To assess responses to ATBC, we transfected CV-1 cells with GAL4 SXR-LBD, in which the yeast 1, 3, or 10lM ) or 0.1% DMSO for 24 h. Firefly luciferase activity was normalized to that of the Renilla control and presented as relative luciferase activity. Results are expressed as mean ± SD (n ¼ 3). (C) Cell culture medium exposed to ATBC from PVDC food wrap activates SXR-mediated transcription of CYP3A4. Two 2-cm squares of PVDC wrap or polyethylene wrap was immersed in 4 ml DMEM containing 10% charcoal-stripped FCS at 37°C for 30 min or 2 h. The medium was filter-sterilized and used for the luciferase reporter assay. CV1 cells were transiently transfected with human SXR or empty expression vector (mock) together with the XREM-CYP3A4-LUC reporter and the phRL-TK transfection control plasmid. After transfection, cells were treated with the plastic wrap-exposed medium for 24 h. Firefly luciferase activity was normalized to that of the Renilla control and presented as relative luciferase activity. Results are expressed as mean ± SD (n ¼ 3). (D) ATBC activates SXR in different species. Chimeric receptors consisting of the Gal4 DNA-binding domain and the ligand-binding domain of human, rat, mouse, rabbit, or beagle SXR were cotransfected into CV-1 cells with the 53 UAS-TK-LUC reporter and phRL-TK transfection control plasmid. After transfection, cells were treated with 0.1% DMSO or RFP, PCN, or ATBC (10lM) for 24 h. Firefly luciferase activity was normalized to that of the Renilla control and presented as relative luciferase activity. Results are expressed as mean ± SD (n ¼ 3).
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463 GAL4 DBD is fused to the SXR-LBD of human, rabbit, rat, mouse, or dog (beagle) origin. After transfection, cells were treated with RFP, PCN, or ATBC (10lM) (Fig. 2D) . RFP was a strong agonist of human SXR and a weak agonist of rabbit SXR but had no effect on rat, mouse, or beagle SXR. PCN activated rat, mouse, and rabbit SXR but not human or beagle SXR. In contrast, ATBC activated SXR in all five species, indicating that animal experiments might predict in vivo effects of ATBC on human SXR-mediated transcription.
Subcellular Localization of p160 Coactivators
Transcriptional activation by NRs is mediated by three p160 transcriptional coactivators (SRC1 also called NCOA1, TIF2 also called SRC2, GRIP1, or NCOA2, and TRAM1 also called SRC3, p/CIP, AIB1, ACTR, RAC3, or NCOA3) (Glass and Rosenfeld, 2000) . Since SXR is predominantly expressed in intestine and liver, we determined the expression of these coactivators in rat duodenum and liver by immunohistochemistry.
In the rat duodenum, the coactivators were expressed in the nuclei of intestinal villi (Fig. 3A-C) . Staining of TIF2 was weaker than that of SRC1, and only faint TRAM1 staining was observed in the nuclei with some dot-like staining in the cytoplasm. In contrast, SRC1 was expressed weakly in the rat liver (Fig. 3D) , whereas relatively strong TIF2 expression (Fig. 3E ) was detected in both nuclei and cytoplasm of liver cells in the periportal region and in the nuclei in the perivenous region. TRAM1 was not detected in liver cells but was strongly expressed in the nuclei of Kupffer cells and vascular endothelial cells (Fig. 3F) .
ATBC Recruits SXR Coactivators
We next assessed ligand-induced interactions between SXR and SRC1 or TIF2 with a mammalian two-hybrid assay. The receptor-interacting domains (RIDs) of SRC1 and TIF2 containing three LXXLL motifs were fused to the DBD of GAL4 (GAL4 SRC1-RID and GAL4 TIF2-RID), and the LBD of human SXR was fused to the transactivation domain of the herpesvirus protein VP16 (VP16 SXR-LBD). These constructs were cotransfected into CV-1 cells with a reporter containing five copies of GAL4 UAS. Both GAL4 SRC1-RID (Fig. 4A ) and GAL4 TIF2-RID (Fig. 4B) interacted with wild-type VP16 SXR-LBD in the presence of RFP and ATBC. Although the RFP-induced interactions of SRC1-RID and TIF2-RID with SXR-LBD were similar, the ATBC-induced interaction between TIF2-RID and SXR-LBD was stronger than that of SRC1-RID and SXR-LBD. When the C-terminal-truncated AF2 mutant VP16 SXR-DAF2 was used, neither RFP nor ATBC increased luciferase activity, suggesting that ATBC interacts directly with SXR-LBD to stimulate transcription. 
ATBC Upregulates CYP3A4 in LS174 Cells
RFP induces both CYP3A4 and MDR1 in LS174T cells, which are derived from a human colonic epithelial tumor in which SXR is endogenously expressed (Geick et al., 2001; Oscarson et al., 2007) . To confirm that ATBC induces CYP3A4 in this cell line, LS174T cells were treated with different concentrations of ATBC for 24 h, and CYP3A4 mRNA levels were determined by real-time qRT-PCR. As shown in Figure 5A , CYP3A4 mRNA levels were increased by ATBC in a dose-dependent manner (> 10lM); however, higher concentrations of ATBC than RFP were required for induction.
SXR Knockdown Inhibits ATBC-Induced CYP3A4 Expression
To confirm that ATBC induction of CYP3A4 in LS174T cells requires SXR, we investigated the effects of SXR loss-of-function on ATBC-induced gene expression by qRT-PCR. We also silenced VDR, another regulator of intestinal CYP3A4 (Thummel et al., 2001) . After 24-h transfection with control siRNA, SXRspecific siRNA, or VDR-specific siRNA, the cells were treated with 20lM RFP, 20lM ATBC, 1nM 1,25-D 3 , or DMSO (vehicle) for 48 h. We observed 70-80% lower SXR and VDR mRNA levels using gene-specific siRNAs (see Supplementary  Figure 4 ). CYP3A4 mRNA levels increased in cells transfected with control siRNA after treatment with RFP, ATBC, or 1,25-D 3 (Fig. 5B) . Consistent with a recent published report, the combination of 1,25-D 3 and RFP synergistically upregulated CYP3A4 mRNA (Pavek et al., 2010) . Similarly, we found that the combination of 1,25-D 3 and ATBC synergistically upregulated CYP3A4 mRNA. SXR knockdown significantly reduced CYP3A4 induction by RFP and ATBC but not induction by 1,25-D 3 . Conversely, VDR knockdown significantly reduced CYP3A4 induction by 1,25-D 3 but not induction by RFP or ATBC. In addition, the synergistic effects were lost after SXR and VDR knockdown. Of note, in our SXR knockdown experiment, CYP3A4 induction by RFP was inhibited by SXR siRNA (from 23.3-fold to 1.7-fold); however, some induction occurred by ATBC after SXR knockdown (from 17.8-fold to 5.9-fold), suggesting that nuclear receptor(s) other than SXR, such as the constitutive androstane receptor (CAR), may be partially involved in ATBC-induced CYP3A4 transcription (Faucette et al., 2006 ). Yet, our knockdown experiment indicates that CYP3A4 induction by ATBC is primarily mediated by SXR in LS174T cells, and ATBC and 1,25-D 3 synergistically upregulate CYP3A4 by activating SXR and VDR, respectively.
ATBC Increases CYP3A4 Activity in LS174T Cells
To determine the effects of ATBC on CYP3A4 enzymatic activity in LS174T cells, we used an assay kit containing Luciferin-IPA. This substrate is metabolized specifically by CYP3A4 to release luciferin, which can be quantified by luminescence through reaction with an ATP-luciferase mixture. LS174T cells were treated for 48 h with different concentrations of ATBC, RFP, phenytoin, or DEHP. We found that RFP (10lM) and ATBC (10 or 50lM) increased CYP3A4 activity (Fig. 5C) . ATBC-induced CYP3A4 activity was lower than that induced by RFP but higher than that induced by phenytoin (50lM) or DEHP (50lM), which are known to induce CYP3A4 through SXR. (Luo et al., 2002; Takeshita et al., 2006) .
We also examined the combined effects of 1,25-D 3 with RFP or ATBC on CYP3A4 activity. As shown in Figure 5D , combining 1,25-D 3 with RFP or ATBC resulted in a greater than additive increase in CYP3A4 activity.
ATBC Fails to Induce CYP3A4 in Human Liver Cells
To examine whether ATBC induces CYP3A4 in the liver, cryopreserved human hepatocytes and human hepatocellular (Figs. 6A-C) . In addition, we treated the human hepatocellular carcinoma cell line HepaRG (Kanebratt and Andersson, 2008) with 20lM RFP or ATBC in the presence or absence of 10nM 1,25-D 3 for 48 h (Fig. 6D ). CYP3A4 mRNA levels were then determined by qRT-PCR. As shown in Figures 6A-6D , although RFP increased CYP3A4 mRNA levels, ATBC failed to induce CYP3A4 gene in all the liver cells tested, suggesting that ATBC-induced CYP3A4 expression is intestine specific. The lack of an effect of ATBC in the liver was partially ''rescued'' by co-administration of 1,25-D 3 in HepaRG cells (Fig. 6D) .
The two-hybrid assay results shown in Figure 4 indicate that both SRC1 and TIF2 are recruited to SXR by ATBC induction. Liver cells showed weak expression of SRC1 and strong expression of TIF2 (Fig. 3) . It is not clear how coactivator expression explains the lack of induction by ATBC in the liver. Therefore, we overexpressed SRC1 and TIF2 in HepaRG cells and examined CYP3A4 expression to see whether overexpression of SRC1 in liver cells helps CYP3A induction by ATBC. Although SRC1 rather than TIF2 overexpression enhanced ATBC-treated CYP3A4 expression, the difference was subtle (Supplementary Figure 5) , suggesting that other factor(s) might be involved in the lack of an effect of ATBC in the liver.
ATBC Is an Intestine-Specific Inducer
To obtain in vivo evidence for the intestine-specific effects of ATBC, we treated Wistar rats with PCN or ATBC by intraperitoneal injection for three consecutive days and evaluated the expression of CYP3A1, which corresponds to human CYP3A4, in liver, duodenum, and ileum using qRT-PCR. As shown in Figures 7A and 7B , both PCN and ATBC increased CYP3A1 expression in the duodenum and ileum of rats. However, PCN but not ATBC induced CYP3A1 in the liver (Fig. 7B) , which is consistent with our in vitro analysis. Alternatively, to determine whether oral exposure of ATBC induces CYP3A1 gene induction, rats were treated with PCN and ATBC by daily gavage for 2 days (Fig. 8) . As seen in the intraperitoneal injection study, PCN but not ATBC induced CYP3A1 expression in the liver (Fig. 8C) . Although we failed to observe CYP3A1 induction by ATBC in the duodenum (Fig.  8A ), significant CYP3A1 induction by ATBC was observed in the ileum (Fig. 8B) , indicating that ATBC is likely to be absorbed in the distal portion of the intestine, where ATBC induces CYP3A1 expression. Taken together, our findings indicate that ATBC is an intestine-specific inducer of CYP3A.
DISCUSSION
In this study, we demonstrated that several FDA-approved plasticizers used in food wrap and pharmaceutical excipients activate SXR-mediated expression of CYP3A4, which is involved in metabolizing endogenous steroid hormones and FDA-APPROVED PLASTICIZER INDUCES CYP3A 467 prescription drugs. Tompkins et al. (2010) recently evaluated 19 commonly used pharmaceutical excipients and reported that none activated human SXR or induced CYP3A4 in human primary hepatocytes or LS174T cells. However, Tompkins et al. evaluated only two plasticizers, whereas our study focused specifically on plasticizers.
Of the plasticizers we evaluated, ATBC was the strongest activator of SXR. We showed that gavage of 50 mg/kg ATBC for only 2 days induced CYP3A1 expression in rat ileum. In men, one can be exposed to as much as 57.55 mg of ATBC-containing drugs (USFDA, 2010b) every day. Although ATBC activated human SXR only at high concentrations (> 1lM) in vitro, local concentrations of ATBC at the intestinal membrane might be high enough to activate SXR after ingestion of ATBC-containing products. In a study of the toxicokinetics and metabolism of ATBC in rats (U.S. Environmental Protection Agency, 2003), gastrointestinal absorption of ATBC was rapid (half-time, 1 h; peak blood levels, 2-4 h after dosing) and extensive (at least 67% of the administered dose). A variety of ATBC formulations are used as additives; therefore, animal studies testing these various formulations are needed.
Because of its performance, lack of odor, low toxicity, and low cost, ATBC is a widely used phthalate substitute in pharmaceutical drugs, PVDC food wrap, cosmetics, aerosol hair sprays, medical tubes, flexible vinyl toys, and even artificial food flavoring (Consumer Product Safety Commission, 2010; European Commission, 1999) . The market share of PVDC food wraps in Japan is nearly 80%. Further, the 1981-1983 National Occupational Survey estimated that 106,672 workers in the United States were exposed to ATBC through inhalation and dermal contact (National Institute for Occupational Safety and Health, 1983) . Overall, we may be exposed to considerable levels of ATBC from multiple sources.
In the present study, we found that ATBC induced intestinal but not hepatic CYP3A expression. Intestinal CYP3A plays a prominent role in the first-pass metabolism of a range of oral drugs, whereas hepatic CYP3A is important for their systemic clearance (van Herwaarden et al., 2007) . These tissue-specific effects of ATBC may be due to SXR splice variants (Zhang et al., 2008; Zhou et al., 2009) Intraperitoneal injection of ATBC induces CYP3A1 expression in rat duodenum and ileum but not in liver. Seven-week-old male Wistar rats (each group, n ¼ 3) were given rat SXR ligand PCN (50 mg/kg), ATBC (5 or 50 mg/kg), or DMSO (vehicle control, 1 ml/kg) by intraperitoneal injection for three consecutive days. Twenty-four hours after the third injection, rats were euthanized, and duodenum, ileum, and liver tissues were collected. CYP3A1 expression was analyzed by qRT-PCR, normalized to GAPDH, and expressed relative to controls. Results are presented as mean ± SD (n ¼ 3). *p < 0.05 versus control. Oral administration of ATBC induces CYP3A1 expression in rat ileum but not in duodenum or liver. Seven-week-old male Wistar rats (each group, n ¼ 3) were administered rat SXR ligand PCN (50 mg/kg) or ATBC (50 mg/kg) in corn oil by daily gavage for two consecutive days. Twenty-four hours after the second administration, the rats were euthanized, and duodenum, ileum, and liver were collected. CYP3A1 expression was analyzed by qRT-PCR, normalized to GAPDH, and expressed relative to controls. Results are presented as the mean ± SD (n ¼ 3). *p < 0.05 versus control.
interactions, and subcellular localization. Differential expression of coactivators and/or corepressors may also influence ligand-specific CYP3A expression (Zhou et al., 2004) . Consistent with this idea, our immunohistochemical analysis of liver and duodenum showed that SRC1 was predominantly expressed in intestinal villi, whereas TIF2 was predominantly expressed in hepatocytes. However, overexpression of SRC1 in liver-derived HepaRG cells showed marginal enhancement of ATBC-induced CYP3A4 expression in our study. The loss of CYP3A4 induction by ATBC was partially rescued by 1,25-D 3 treatment in HepaRG cells. Ligand-bound SXR forms a transcriptional complex not only with p160 coactivators but also with other coactivators, and ''cross talks'' with other NRs, such as VDR, CAR, and hepatocyte nuclear factor-4a (Tirona et al., 2003) , which are all important in CYP3A4 regulation. Therefore, it will be interesting to examine the influence of other coactivators and NRs on CYP3A4 regulation by ATBC in the liver.
Long-term treatment with RFP or antiepileptic drugs can cause vitamin D deficiency or osteomalacia by upregulating CYP3A4. VDR also controls intestinal CYP3A4 expression through a feedback mechanism, upregulating CYP3A4 to increase catabolism of 1,25-D 3 when vitamin D levels are high. In the present study, we found that ATBC and 1,25-D 3 synergistically increased CYP3A4 expression and activity in LS174T cells by activating SXR and VDR, respectively. Thus, ATBC may accelerate local vitamin D catabolism, which may in turn reduce calcium absorption by downregulating expression of the TRPV6 calcium transporter.
Drug interactions caused by pharmaceutical excipients are also a concern. Generic drugs accounted for~75% of drug prescriptions in the United States in 2009 (IMS, 2010) . Although generic drugs must contain the same active ingredient as their brand-name counterparts, studies and case reports have described differences in their efficacy (Meredith, 2003) . ATBC is used to plasticize polymers in coatings for capsules, tablets, beads, and granules for taste masking and to produce immediate-release, sustained-release, and enteric formulations (Kennedy, 2006) . The use of different excipients may explain, in part, the lack of bioequivalence of generic drugs. It will be interesting to know whether generic drugs reported to lack bioequivalence contain SXR-activating plasticizers.
In summary, we demonstrated that several FDA-approved plasticizers, ATBC in particular, activate SXR. Results of our in vitro and in vivo experiments suggest that ATBC is an intestine-specific inducer of CYP3A through activation of SXR. The FDA reports that some patients may ingest almost 60 mg ATBC daily as a pharmaceutical excipient. Furthermore, we are exposed to ATBC from various environmental products. We suggest that products containing ATBC be used with care because they may alter metabolism of endogenous steroid hormones and prescription drugs. 
